

Table 2. Pathological response rates to neoadjuvant arm reported in the NADINA study

Pathological response	Proportion of patients	Estimated 12-month recurrence free survival according to response
Major*	125 (59%)	95.1% (99.9% CI, 87.4 to 99.9)
Partial†	17 (8%)	76.1% (99.9% CI, 44.4 to 99.9)
Non-response§	56 (26.4%)	57.0% (99.9% CI, 33.3 to 97.6)
* ≤ 10% residual viable tumour † 11 to 50% residual viable tumour § >50% residual viable tumour		